Alimera readies for Iluvien resubmission, partner pSivida says
This article was originally published in Scrip
Executive Summary
With approvals racking up in Europe for Iluvien (fluocinolone acetonide intravitreal insert) – most recently in Germany, Austria, France, Portugal and the UK – pSivida was eager to tell investors that its partner Alimera Sciences is ready to resubmit its application to FDA for marketing in the US, where the company has struggled to make it to the finish line with the drug as a treatment for diabetic macular edema (DME) (scripintelligence, 27 July 2012, 20 July 2012, 7 June 2012, 8 May 2012, 29 February 2012).